Reports Q3 revenue $3,017, consensus $170,000. "We continue to build momentum with our UK programs, while initiating our foothold in the U.S. The recent purchase order from HealthFleet marks the beginning of our commercialization efforts in the U.S., integrating our proBEAT technology into HealthFleet’s RestoreHealth program to potentially improve diabetes management and weight loss. This is a significant step forward towards the integration of our sensor technology into existing diabetes management programs in the U.S.," commented Nemaura CEO Dr. Faz Chowdhury. "With Miboko, the encouraging early patient data from our UK NHS Miboko study that demonstrated weight loss in 100% of participants is very encouraging and bodes well for the future of that program. There are obviously many weight loss programs on the market, but this early Miboko data exceeds the results seen in some of these other programs. With our balance sheet strengthened by the recent capital raise, we are better positioned to execute on our commercialization efforts and strategic goals in 2023."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on NMRD:
- Nemaura Medical Reports Fiscal Third Quarter 2023 Results and Provides Business Update
- Nemaura Medical to Participate in Fireside Chat at the MicroCap Rodeo Winter Wonderland Best Ideas 2023 Virtual Conference
- Nemaura Medical Announces Closing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement
- Nemaura Medical Announces Pricing of Approximately $8.4 Million Registered Direct Offering and Concurrent Private Placement
- Nemaura Medical prices $8.4M registered direct offering